Design and study of peptide-based inhibitors of amylin cytotoxicity

The incidence of type II diabetes is on the increase each year and the World Health Organisation (WHO) predicts there to be over 360 million diabetic patients worldwide by the year 2030. Deposits consisting mainly of a small protein, called islet amyloid polypeptide (amylin), which aggregates into o...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry letters Vol. 20; no. 4; pp. 1360 - 1362
Main Authors: Muthusamy, Karen, Arvidsson, Per I., Govender, Patrick, Kruger, Hendrik G., Maguire, Glenn E.M., Govender, Thavendran
Format: Journal Article
Language:English
Published: Amsterdam Elsevier Ltd 15-02-2010
Elsevier
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The incidence of type II diabetes is on the increase each year and the World Health Organisation (WHO) predicts there to be over 360 million diabetic patients worldwide by the year 2030. Deposits consisting mainly of a small protein, called islet amyloid polypeptide (amylin), which aggregates into oligo-/polymeric beta sheet structures is responsible for cytoxicity to the pancreatic β-cells, thus inhibition of this process has been explored as a potential prevention or treatment. N-Methylated and non N-methylated peptides spanning the length of amylin 1–37 were synthesised and evaluated for their inhibition of full length amylin mediated cytoxicity to RIN-5F cells. The non N-methylated peptides were very effective in inhibiting the cytotoxicity while the N-methylated peptides were not. Both the N-methylated and non N-methylated versions of the 29-34 region were equally effective.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0960-894X
1464-3405
1464-3405
DOI:10.1016/j.bmcl.2010.01.004